1
|
Talmadge JE, Donkor M and Scholar E:
Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer
Metastasis Rev. 26:373–400. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Qi W, Huang X and Wang J: Correlation
between Th17 cells and tumor microenvironment. Cell Immunol.
285:18–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Talmadge JE: Immune cell infiltration of
primary and metastatic lesions: Mechanisms and clinical impact.
Semin Cancer Biol. 21:131–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Josefowicz SZ, Lu LF and Rudensky AY:
Regulatory T cells: Mechanisms of differentiation and function.
Annu Rev Immunol. 30:531–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bailey SR, Nelson MH, Himes RA, Li Z,
Mehrotra S and Paulos CM: Th17 cells in cancer: The ultimate
identity crisis. Front Immunol. 5:2762014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen Z and O'Shea JJ: Th17 cells: A new
fate for differentiating helper T cells. Immunol Res. 41:87–102.
2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Peck A and Mellins ED: Plasticity of
T-cell phenotype and function: The T helper type 17 example.
Immunology. 129:147–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Barbi J, Pardoll D and Pan F: Treg
functional stability and its responsiveness to the
microenvironment. Immunol Rev. 259:115–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Stritesky GL, Yeh N and Kaplan MH: IL-23
promotes maintenance but not commitment to the Th17 lineage. J
Immunol. 181:5948–5955. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kryczek I, Banerjee M, Cheng P, Vatan L,
Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et
al: Phenotype, distribution, generation and functional and clinical
relevance of Th17 cells in the human tumor environments. Blood.
114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Azzazene D, Al Thawadi H, Al Farsi H,
Besbes S, Geyl C, Mirshahi S, Pardo J, Faussat AM, Jeannette S,
Therwath A, et al: Plasma endothelial protein C receptor influences
innate immune response in ovarian cancer by decreasing the
population of natural killer and TH17 helper cells. Int J Oncol.
43:1011–1018. 2013.PubMed/NCBI
|
13
|
Muranski P, Boni A, Antony PA, Cassard L,
Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
et al: Tumor-specific Th17-polarized cells eradicate large
established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Sfanos KS, Bruno TC, Maris CH, Xu L,
Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG:
Phenotypic analysis of prostate-infiltrating lymphocytes reveals
TH17 and Treg skewing. Clin Cancer Res. 14:3254–3261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Demaria S, Pikarsky E, Karin M, Coussens
LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo
E, et al: Cancer and inflammation: Promise for biologic therapy. J
Immunother. 33:335–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Guarino V, Castellone MD, Avilla E and
Melillo RM: Thyroid cancer and inflammation. Mol Cell Endocrinol.
321:94–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Okayasu I: The relationship of lymphocytic
thyroiditis to the development of thyroid carcinoma. Endocr Pathol.
8:225–230. 1997. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kebebew E, Treseler PA, Ituarte PH and
Clark OH: Coexisting chronic lymphocytic thyroiditis and papillary
thyroid cancer revisited. World J Surg. 25:632–637. 2001.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Ugolini C, Basolo F, Proietti A, Vitti P,
Elisei R, Miccoli P and Toniolo A: Lymphocyte and immature
dendritic cell infiltrates in differentiated, poorly
differentiated, and undifferentiated thyroid carcinoma. Thyroid.
17:389–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Wang Y and Wang W: Increasing incidence of
thyroid cancer in Shanghai, China, 1983–2007. Asia Pac J Public
Health. 27:223–229. 2015. View Article : Google Scholar
|
21
|
Nikiforov YE: Molecular diagnostics of
thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
|
22
|
Zanetti BR, Carvalho-Galano DF, Feitosa
NL, Hassumi-Fukasawa MK, Miranda-Camargo FA, Maciel LM,
Ribeiro-Silva A and Soares EG: Differential expression of
immune-modulatory molecule HLA-E in non-neoplastic and neoplastic
lesions of the thyroid. Int J Immunopathol Pharmacol. 26:889–896.
2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
de Figueiredo Feitosa NL, Crispim JC,
Zanetti BR, Magalhães PK, Soares CP, Soares EG, Neder L, Donadi EA
and Maciel LM: HLA-G is differentially expressed in thyroid
tissues. Thyroid. 24:585–592. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
25
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, ; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et
al: Revised American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
27
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Muzza M, Degl'Innocenti D, Colombo C,
Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG
and Fugazzola L: The tight relationship between papillary thyroid
cancer, autoimmunity and inflammation: Clinical and molecular
studies. Clin Endocrinol (Oxf). 72:702–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
French JD, Weber ZJ, Fretwell DL, Said S,
Klopper JP and Haugen BR: Tumor-associated lymphocytes and
increased FoxP3+ regulatory T cell frequency correlate with more
aggressive papillary thyroid cancer. J Clin Endocrinol Metab.
95:2325–2333. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Ouyang W, Kolls JK and Zheng Y: The
biological functions of T helper 17 cell effector cytokines in
inflammation. Immunity. 28:454–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yang B, Kang H, Fung A, Zhao H, Wang T and
Ma D: The role of interleukin 17 in tumour proliferation,
angiogenesis, and metastasis. Mediators Inflamm. 2014:6237592014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Mizutani K, Sud S, McGregor NA,
Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H and Pienta KJ:
The chemokine CCL2 increases prostate tumor growth and bone
metastasis through macrophage and osteoclast recruitment.
Neoplasia. 11:1235–1242. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ngiow SF, Teng MW and Smyth MJ: A balance
of interleukin-12 and −23 in cancer. Trends Immunol. 34:548–555.
2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF and
Peng G: Tumor microenvironments direct the recruitment and
expansion of human Th17 cells. J Immunol. 184:1630–1641. 2010.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Kastelein RA, Hunter CA and Cua DJ:
Discovery and biology of IL-23 and IL-27: Related but functionally
distinct regulators of inflammation. Annu Rev Immunol. 25:221–242.
2007. View Article : Google Scholar : PubMed/NCBI
|
36
|
Stritesky GL, Yeh N and Kaplan MH: IL-23
promotes maintenance but not commitment to the Th17 lineage. J
Immunol. 181:5948–5955. 2008. View Article : Google Scholar : PubMed/NCBI
|
37
|
Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW,
Chun GT, Kim NS, Yie SW, Byeon WH, Eom SH, et al: Mechanisms
underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse
macrophages and their implications for angiogenesis. J Leukoc Biol.
81:557–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Langowski JL, Zhang X, Wu L, Mattson JD,
Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M:
IL-23 promotes tumour incidence and growth. Nature. 442:461–465.
2006. View Article : Google Scholar : PubMed/NCBI
|
39
|
Chizzolini C, Chicheportiche R, Alvarez M,
de Rham C, Roux-Lombard P, Ferrari-Lacraz S and Dayer JM:
Prostaglandin E2 synergistically with interleukin-23 favors human
Th17 expansion. Blood. 112:3696–3703. 2008. View Article : Google Scholar : PubMed/NCBI
|
40
|
Galand C, Donnou S, Crozet L, Brunet S,
Touitou V, Ouakrim H, Fridman WH, Sautès-Fridman C and Fisson S:
Th17 cells are involved in the local control of tumor progression
in primary intraocular lymphoma. PLoS One. 6:e246222011. View Article : Google Scholar : PubMed/NCBI
|
41
|
Noonan K, Marchionni L, Anderson J,
Pardoll D, Roodman GD and Borrello I: A novel role of
IL-17-producing lymphocytes in mediating lytic bone disease in
multiple myeloma. Blood. 116:3554–3563. 2010. View Article : Google Scholar : PubMed/NCBI
|
42
|
Charles KA, Kulbe H, Soper R,
Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P,
Thompson RG, Kollias G, Smyth JF, et al: The tumor-promoting
actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in
mice and humans. J Clin Invest. 119:3011–3023. 2009. View Article : Google Scholar : PubMed/NCBI
|
43
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Zhang JP, Yan J, Xu J, Pang XH, Chen MS,
Li L, Wu C, Li SP and Zheng L: Increased intratumoral
IL-17-producing cells correlate with poor survival in
hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009.
View Article : Google Scholar : PubMed/NCBI
|